Antiviral nasal spray for common colds or more severe respiratory diseases

Start-up G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

16-Apr-2024 - G.ST Antivirals, aspin-off from the Medical University of Vienna applying innovative, host cell-based strategies to develop broad-spectrum antivirals against respiratory tract infections, announced the appointment of Ronald Bruce Turner, MD, as new Chief Medical Officer (CMO). An expert in the ...

Game changer in fighting cancer: BioCopy expands corporate portfolio with acquisition of start-up Perspix Biotech

"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"

11-Apr-2024 - BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...

A new path to active ingredient diversity

26-Mar-2024 - Many important drugs, such as antibiotics and cancer drugs, are derived from natural substances from bacteria. The bacterial enzymes that produce these active ingredients are considered ideal tools for synthetic biology due to their modular design. By researching protein evolution, a team led by ...

A navigation system to combat bottlenecks in medication supply

Tool for supervisory authorities

22-Jan-2024 - A new model designed by ETH Zurich researchers measures how flexible medication distribution systems are in real time. It shows that supply shortages can be eased if pharmaceutical wholesalers coordinate their inventories and reroute scarce products as flexibly as possible along existing supply ...

CSIC researchers identify a new class of antivirals against covid-19

New antivirals act by blocking virus entry into the host cell through interaction with the 'spike' protein

07-Aug-2023 - Researchers from the Consejo Superior de Investigaciones Científicas at the Instituto de Química Médica (IQM-CSIC), the Instituto de Biología Integrativa de Sistemas (I2SysBio-CSIC-UV) and the Instituto de Biomedicina de Valencia (IBV-CSIC), members of the Plataforma Temática Interdisciplinar ...

Novel compound for targeted tumor therapy in patients with soft tissue sarcoma

Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001

04-Apr-2023 - Thermosome announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible Ethics Committee to conduct a Phase 1 trial with its lead program THE001 in Germany. Patient enrollment is expected to start in Q2, 2023. The primary ...

Drug shortages: These factors lead to supply bottlenecks in the pharmaceutical industry

Competition between generics manufacturers makes supply chains more vulnerable

31-Mar-2023 - In a recent study, Prof. Dr. Kai Hoberg (KLU), Prof. Dr. David Francas (University of Applied Sciences Worms) and Stephan Mohr (Frankfurt School of Finance and Management) looked into which conditions affect the availability of drugs in Germany. One key finding: while competition between generics ...

"Dr Jekyll and Mr Hyde" technique to fight cancer

Viennese start-up develops novel, precise anti-cancer drugs

06-Mar-2023 - RIANA Therapeutics, a promising pharmaceutical start-up recently spun out of the University of Veterinary Medicine Vienna (Vetmeduni), aims to develop novel therapeutics for cancer patients based in part on scientific findings from Vetmeduni’s Moriggl research group (Moriggl Lab). The ...

Million investment for lung cancer therapy

Belgian biotech start-up will use funding to start first-in-human clinical study for lead drug candidate in lung cancer

23-Jan-2023 - DeuterOncology, a clinical-stage drug development company, announces the closing of its €5.65 million ($6.1M) Series A financing, with participation from historical investor Newton Biocapital and new investors Noshaq and Investsud Tech. This funding will enable the company to start the phase I ...

Digital twins, new cancer treatments and three unicorns

A grand total of 26 spin-​offs were founded at ETH Zurich in 2022

10-Jan-2023 - Their businesses range from new cancer drugs and sustainable water bottles to digital mapping of urban traffic flows. The ETH spin-​off family also welcomed three new unicorns and raised 1.2 billion Swiss francs in fresh capital. These newly founded spin-offs cover a wide variety of fields and ...